Experience high-quality research outcomes with Top Shelf Peptides' CJC-1295 (Without DAC), 10mg vial.

CJC-1295

Advanced Growth Hormone & Recovery Research Peptide

CJC-1295 is a synthetic Growth Hormone-Releasing Hormone (GHRH) analogue widely studied for its interaction with growth-hormone signalling, IGF-1 pathways, recovery biology, metabolic regulation, and healthy-ageing research.

Researchers investigating muscle recovery, tissue repair, metabolic adaptation, sleep quality, body composition, and endocrine signalling are particularly interested in CJC-1295 because of its apparent ability to stimulate the body’s natural growth-hormone release pathways.

Unlike direct growth-hormone administration models, CJC-1295 is studied for its interaction with the body’s own:

• Growth Hormone-Releasing Hormone (GHRH) pathways

• Pituitary signalling systems

• Endocrine feedback mechanisms

Top Shelf Peptides supplies high-purity CJC-1295 research compounds within Australia with fast domestic dispatch and batch-verified analytical testing.

Supplied as a lyophilised (freeze-dried) powder, CJC-1295 is intended strictly for laboratory and in-vitro research purposes only.

What Is CJC-1295?

CJC-1295 is a synthetic peptide analogue designed to mimic the biological activity of:

Growth Hormone-Releasing Hormone (GHRH)

Researchers investigate CJC-1295 because it appears to stimulate the pituitary gland to release:

• Growth Hormone (GH)

• Insulin-Like Growth Factor 1 (IGF-1)

through natural endocrine-signalling pathways.

Its endocrine-regulation profile has made it one of the most recognised compounds within growth-hormone and recovery-focused research.

How Researchers Study CJC-1295

Growth Hormone Signalling Research

One of the primary focuses of CJC-1295 research involves:

• Growth-hormone release pathways

• IGF-1 signalling

• Endocrine adaptation

• Pituitary-gland activity

• Hormonal-regulation mechanisms

Researchers investigate whether stimulating natural GH pathways may influence broader recovery and metabolic systems.

CJC-1295 With DAC vs Without DAC

Researchers commonly investigate two primary forms of CJC-1295:

CJC-1295 With DAC

DAC stands for:

Drug Affinity Complex

This modification allows the peptide to bind to serum albumin, significantly extending its half-life.

Researchers investigate DAC-modified CJC-1295 for:

• Extended GH-signalling activity

• Longer-duration endocrine stimulation

• Reduced administration frequency

• Sustained IGF-1 pathway interaction

Experimental models commonly investigate half-life activity ranging from approximately:

• 6 to 8 days

CJC-1295 Without DAC (Mod GRF 1-29)

The non-DAC version has a significantly shorter half-life and is commonly studied for:

• Pulsatile GH release

• Short-duration endocrine signalling

• Controlled pituitary stimulation

• More precise timing-related protocols

Researchers often investigate this format for tighter modulation of physiological growth-hormone signalling patterns.

Muscle & Recovery Research

CJC-1295 is widely investigated within:

• Muscle-recovery research

• Tissue-repair studies

• Recovery-adaptation models

• Lean-mass signalling pathways

• Connective tissue research

Researchers continue studying how GH and IGF-1 signalling may influence broader regenerative and recovery-related biology.

Metabolic & Fat-Loss Research

Researchers additionally investigate CJC-1295 for its interaction with:

• Lipolysis pathways

• Fat metabolism

• Body-composition signalling

• Metabolic adaptation

• Energy-utilisation systems

Growth-hormone-related compounds continue attracting strong interest within metabolic and body-composition research.

Sleep & Recovery Pathway Research

Researchers commonly study CJC-1295 for its apparent involvement in:

• Sleep-quality pathways

• Recovery-related signalling

• Circadian endocrine interactions

• Restorative biological systems

Because natural growth-hormone release is strongly associated with sleep cycles, this remains a major area of interest.

Combination Peptide Research

CJC-1295 is frequently investigated alongside other growth-hormone secretagogue compounds including:

• Ipamorelin

• GHRP-6

• Growth-hormone-releasing peptides

Researchers study these combinations for their interaction with:

• Synergistic GH-signalling pathways

• Endocrine amplification

• Recovery adaptation

• Body-composition signalling

Combination peptide systems remain highly popular within endocrine-focused research environments.

Healthy-Ageing & Longevity Research

Researchers investigating healthy-ageing biology continue studying CJC-1295 because of its apparent interaction with:

• Recovery pathways

• Cellular-resilience systems

• Sleep-related endocrine signalling

• Tissue-repair mechanisms

• Age-related hormonal decline

This has contributed to growing interest within longevity-focused research communities.

Research Integrity & Safety Context

CJC-1295 remains an investigational compound within many research environments.

Researchers continue evaluating:

• Endocrine signalling pathways

• Long-term GH-related interactions

• Hormonal adaptation mechanisms

• Recovery biology

• Metabolic-response patterns

Because endocrine compounds influence highly complex biological systems, analytical verification and responsible laboratory handling remain critically important.

Product Information

All products supplied by Top Shelf Peptides are sourced, tested, and dispatched entirely within Australia with fast domestic shipping and batch-specific Certificate of Analysis (CoA) verification available through the CoA Library or by scanning the QR code supplied with each product.

⚠ For laboratory and in-vitro research purposes only. Not for human consumption.

⚠ None of the products supplied by Top Shelf Peptides are approved therapeutic goods unless expressly stated otherwise.

⚠ By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.